Emily Hinchcliff

Also affiliated with Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “State of the science: Contemporary front-line treatment of advanced ovarian cancer”.

State of the science: Contemporary front-line treatment of advanced ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.021

N/A

0.505DataRank · unranked

28 citations

Shannon N. Westin, Thomas J. Herzog, Emily Hinchcliff

Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.024

N/A

0.269DataRank · unranked

5 citations

Jennifer Rumpf, Ravin Ratan, Nicole D. Fleming, Amir A. Jazaeri, Bryan Fellman +3 more

EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5573

N/A

0.104DataRank · unranked

1 citations

Emily Hinchcliff, Shuqi Wang, Amir A. Jazaeri, Anil K. Sood, Bryan Fellman +14 more

Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer

iScience(2024)10.1016/j.isci.2024.109801

N/A

0DataRank · unranked

5 citations

Emily Hinchcliff, Elisabeth Gardiner, Reshma Rangwala, Kathryn Lito, Bryan Fellman +6 more

PPP2R1A mutations portend improved survival after cancer immunotherapy

Nature(2025)10.1038/s41586-025-09203-8

N/A

0DataRank · unranked

29 citations

Anne Knisely, Mitsutake Yano, Minghao Dang, Emily Hinchcliff, Sanghoon Lee +36 more

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

Cancer(2023)10.1002/cncr.35126

N/A

0DataRank · unranked

18 citations

Anne Knisely, Naomi Adjei, Bryan Fellman, Ying Yuan, Ami Patel +16 more

Has dose-dense chemotherapy met an ICONic end?

The Lancet Oncology(2020)10.1016/s1470-2045(20)30276-x

N/A

0DataRank · unranked

1 citations

Larissa A. Meyer, Shannon N. Westin, Emily Hinchcliff

PARP inhibition in the ovarian cancer patient: Current approvals and future directions

Pharmacology & Therapeutics(2020)10.1016/j.pharmthera.2020.107588

N/A

0DataRank · unranked

16 citations

Monica Avila, Emily Hinchcliff, Robert L. Coleman, Shannon N. Westin, Katherine C. Kurnit